SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-029554
Filing Date
2021-03-01
Accepted
2021-03-01 06:01:52
Documents
12
Period of Report
2021-02-24
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm218199d1_8k.htm   iXBRL 8-K 26325
  Complete submission text file 0001104659-21-029554.txt   199178

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA srne-20210224.xsd EX-101.SCH 3223
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20210224_lab.xml EX-101.LAB 34592
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20210224_pre.xml EX-101.PRE 22735
5 EXTRACTED XBRL INSTANCE DOCUMENT tm218199d1_8k_htm.xml XML 3490
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36150 | Film No.: 21693518
SIC: 2836 Biological Products, (No Diagnostic Substances)